KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.90 USD
+0.19 (2.79%)
Updated May 10, 2024 03:56 PM ET
3-Hold of 5 3
F Value B Growth D Momentum D VGM
Brokerage Reports
KALA BIO, Inc. [KALA]
Reports for Purchase
Showing records 361 - 365 ( 365 total )
Company: KALA BIO, Inc.
Industry: Unclassified
Kala Submits NDA for INVELTYS for Post-Op Pain and Inflammation
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Unclassified
Weakness Due to Future Generic Restasis is a Buying Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: KALA BIO, Inc.
Industry: Unclassified
Company: KALA BIO, Inc.
Industry: Unclassified
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: KALA BIO, Inc.
Industry: Unclassified
We are initiating coverage of KALA with an OUTPERFORM rating and $46 twelve month price target
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L